129 related articles for article (PubMed ID: 11145438)
1. Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group.
Wisløff F; Gulbrandsen N
Acta Oncol; 2000; 39(7):809-13. PubMed ID: 11145438
[TBL] [Abstract][Full Text] [Related]
2. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
Wisløff F; Hjorth M; Kaasa S; Westin J
Br J Haematol; 1996 Aug; 94(2):324-32. PubMed ID: 8759893
[TBL] [Abstract][Full Text] [Related]
3. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.
Wisløff F; Eika S; Hippe E; Hjorth M; Holmberg E; Kaasa S; Palva I; Westin J
Br J Haematol; 1996 Mar; 92(3):604-13. PubMed ID: 8616024
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group.
Wisløff F; Hjorth M
Br J Haematol; 1997 Apr; 97(1):29-37. PubMed ID: 9136939
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.
Gulbrandsen N; Wisløff F; Brinch L; Carlson K; Dahl IM; Gimsing P; Hippe E; Hjorth M; Knudsen LM; Lamvik J; Lenhoff S; Løfvenberg E; Nesthus I; Nielsen JL; Turesson I; Westin J;
Med Oncol; 2001; 18(1):65-77. PubMed ID: 11778972
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Delforge M; Dhawan R; Robinson D; Meunier J; Regnault A; Esseltine DL; Cakana A; van de Velde H; Richardson PG; San Miguel JF
Eur J Haematol; 2012 Jul; 89(1):16-27. PubMed ID: 22469559
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C
J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228
[TBL] [Abstract][Full Text] [Related]
12. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
13. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
Verelst SG; Termorshuizen F; Uyl-de Groot CA; Schaafsma MR; Ammerlaan AH; Wittebol S; Sinnige HA; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst HM; Sonneveld P; Wijermans PW;
Ann Hematol; 2011 Dec; 90(12):1427-39. PubMed ID: 21472373
[TBL] [Abstract][Full Text] [Related]
14. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
Westin J; Rödjer S; Turesson I; Cortelezzi A; Hjorth M; Zador G
Br J Haematol; 1995 Mar; 89(3):561-8. PubMed ID: 7734355
[TBL] [Abstract][Full Text] [Related]
15. Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden.
Björkholm M
Eur J Cancer; 1991; 27 Suppl 4():S51-2. PubMed ID: 1799480
[No Abstract] [Full Text] [Related]
16. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.
Zee B; Cole B; Li T; Browman G; James K; Johnston D; Sugano D; Pater J
J Clin Oncol; 1998 Aug; 16(8):2834-9. PubMed ID: 9704736
[TBL] [Abstract][Full Text] [Related]
17. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
18. [Quality of life and tolerance of maintenance therapy in patients with multiple myeloma].
Adam Z; Pour L; Svobodník A; Scudla V; Salajka F; Vytrasová M; Bacovský J; Schützová M; Koza V; Sumná E; Franková H; Lehanka F; Gumulec J; Stavarová Y; Cahová S; Vránová M; Dostálová V; Kessler P; Walterová L; Meluzínová I; Seifertová N; Sláma O; Büchler T; Krejcí M; Bencíková V; Nykodýmová V; Dusek L; Hájek R;
Vnitr Lek; 2002 Mar; 48(3):216-29. PubMed ID: 11968583
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.
Nord E; Wisløff F; Hjorth M; Westin J
Pharmacoeconomics; 1997 Jul; 12(1):89-103. PubMed ID: 10169390
[TBL] [Abstract][Full Text] [Related]
20. Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group.
Johnsen HE; Klausen TW; Boegsted M; Lenhoff S; Gimsing P; Christiansen I; Gedde-Dahl T; Lindås R; Mellqvist UH;
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):290-6. PubMed ID: 20709667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]